Encompass Health reaffirms FY2022 guidance at Mizuho CEO Insight Series

Encompass Health Corp

Reiterates FY2022 net operating revenues guidance of $4.32B to $4.35B.
Reaffirms adjusted EBITDA guidance of $800M to $820M.
Reaffirms adjusted EPS from continuing ops guidance of $2.71 to $2.86.
CEO Mark Tarr participating in Mizuho CEO Insight Series on Nov 14, 2022.

item 7.01

Encompass Health Corp filing history →

Source: SEC EDGAR

accession 0000785161-22-000050

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.